Journal of Diabetes and Its Complications
Volume 24, Issue 3 , Pages 209-213 , May 2010

Sitagliptin treatment of patients with type 2 diabetes does not affect CD4+ T-cell activation

  • Perrin C. White

      Affiliations

    • Department of Pediatrics, UT Southwestern Medical Center, Dallas, TX 75390-9063, USA
    • Corresponding Author InformationCorresponding author. UT Southwestern Medical Center, Dallas, TX 75390-9063, USA. Tel.: +1 214 648 3501; fax: +1 214 648 9772.
    • PCW is the Audry Newman Rapoport Distinguished Chair in Pediatric Endocrinology.
    • ,
  • Heidi Chamberlain-Shea

      Affiliations

    • Endocrine Associates of Dallas, Dallas, TX 75093, USA
    • ,
  • Maria-Teresa de la Morena

      Affiliations

    • Department of Pediatrics, UT Southwestern Medical Center, Dallas, TX 75390-9063, USA

Received 21 May 2009 ,Revised 10 August 2009 ,Accepted 10 September 2009.

References 

  1. Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: Systematic review and meta-analysis. JAMA. 2007;298:194–206
  2. Augustine NH, Pasi BM, Hill HR. Comparison of ATP production in whole blood and lymphocyte proliferation in response to phytohemagglutinin. Journal of Clinical Laboratory Analysis. 2007;21:265–270
  3. Aytac U, Dang NH. CD26/dipeptidyl peptidase IV: a regulator of immune function and a potential molecular target for therapy. Current Drug Targets. Immune, Endocrine and Metabolic Disorders. 2004;4:11–18
  4. Basinski TM, Holzmann D, Eiwegger T, Zimmermann M, Klunker S, Meyer N, et al. Dual nature of T cell-epithelium interaction in chronic rhinosinusitis. The Journal of Allergy and Clinical Immunology. 2009;124:74–80
  5. Buttgereit F, Burmester GR, Brand MD. Bioenergetics of immune functions: fundamental and therapeutic aspects. Immunology Today. 2000;21:192–199
  6. Deacon CF, Johnsen AH, Holst JJ. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. The Journal of Clinical Endocrinology and Metabolism. 1995;80:952–957
  7. Kameoka J, Sato T, Torimoto Y, Sugita K, Soiffer RJ, Schlossman SF, et al. Differential CD26-mediated activation of the CD3 and CD2 pathways after CD6-depleted allogeneic bone marrow transplantation. Blood. 1995;85:1132–1137
  8. Kato A, Schleimer RP. Beyond inflammation: Airway epithelial cells are at the interface of innate and adaptive immunity. Current Opinion Immunology. 2007;19:711–720
  9. Kowalski R, Post D, Schneider MC, Britz J, Thomas J, Deierhoi M, et al Immune cell function testing: An adjunct to therapeutic drug monitoring in transplant patient management. Clinical Transplantation. 2003;17:77–88
  10. Kowalski RJ, Post DR, Mannon RB, Sebastian A, Wright HI, Sigle G, et al Assessing relative risks of infection and rejection: A meta-analysis using an immune function assay. Transplantation. 2006;82:663–668
  11. Kowalski RJ, Zeevi A, Mannon RB, Britz JA, Carruth LM. Immunodiagnostics: Evaluation of functional T-cell immunocompetence in whole blood independent of circulating cell numbers. J Immunotoxicol. 2007;4:225–232
  12. Marguet D, Baggio L, Kobayashi T, Bernard AM, Pierres M, Nielsen PF, et al. Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26. Proceeding of the National Academy of Sciences of the United State of America. 2000;97:6874–6879
  13. Nathan DM. Finding new treatments for diabetes—how many, how fast…how good?. New England Journal of Medicine. 2007;356:437–440
  14. Preller V, Gerber A, Togni M, Wrenger S, Schraven B, Rocken C, et al. CD26/DP IV in T cell activation and autoimmunity. Advances in Experimental Medicine and Biology. 2006;575:187–193
  15. Reinhold D, Bank U, Buhling F, Lendeckel U, Faust J, Neubert K, et al. Inhibitors of dipeptidyl peptidase IV induce secretion of transforming growth factor-beta 1 in PWM-stimulated PBMC and T cells. Immunology. 1997;91:354–360
  16. Richter B, Bandeira-Echtler E, Bergerhoff K, Lerch C. Emerging role of dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes. Vasc Health Risk Manag. 2008;4:753–768
  17. Richter B, Bandeira-Echtler E, Bergerhoff K, Lerch CL. Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews. 2008;CD006739
  18. Steinbrecher A, Reinhold D, Quigley L, Gado A, Tresser N, Izikson L, et al Targeting dipeptidyl peptidase IV (CD26) suppresses autoimmune encephalomyelitis and up-regulates TGF-beta 1 secretion in vivo. Journal of Immunology. 2001;166:2041–2048

☆ Disclosure statement: The authors have nothing to disclose.

PII: S1056-8727(09)00092-0

doi: 10.1016/j.jdiacomp.2009.09.001

Journal of Diabetes and Its Complications
Volume 24, Issue 3 , Pages 209-213 , May 2010

Article Tools

* Image Usage & Resolution